4/22
07:30 am
tgtx
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Medium
Report
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
4/18
10:37 pm
tgtx
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook [Seeking Alpha]
Medium
Report
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook [Seeking Alpha]
4/18
09:32 pm
tgtx
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Medium
Report
A Look At TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum [Yahoo! Finance]
4/16
05:53 am
tgtx
TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]
Low
Report
TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]
4/16
01:08 am
tgtx
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]
Low
Report
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI [Yahoo! Finance]
4/15
07:30 am
tgtx
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Low
Report
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
3/31
07:08 pm
tgtx
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside [Seeking Alpha]
Low
Report
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside [Seeking Alpha]
3/24
01:36 pm
tgtx
A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility [Yahoo! Finance]
Low
Report
A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility [Yahoo! Finance]
3/19
07:30 am
tgtx
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Low
Report
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
3/16
04:26 pm
tgtx
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop [Yahoo! Finance]
Medium
Report
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop [Yahoo! Finance]
3/10
08:12 am
tgtx
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
Low
Report
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) [Yahoo! Finance]
3/9
12:35 pm
tgtx
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
Low
Report
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? [Yahoo! Finance]
3/9
07:58 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis [Yahoo! Finance]
3/9
07:30 am
tgtx
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
Low
Report
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
3/9
03:34 am
tgtx
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
Low
Report
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story [Yahoo! Finance]
3/8
04:33 pm
tgtx
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
Low
Report
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio [Yahoo! Finance]
3/8
01:33 pm
tgtx
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
Low
Report
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI-Led Earnings And Autoimmune Pipeline Updates [Yahoo! Finance]
3/8
06:33 am
tgtx
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
Low
Report
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings [Yahoo! Finance]
3/6
07:30 am
tgtx
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Low
Report
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
3/1
04:40 am
tgtx
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
2/28
07:02 pm
tgtx
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
Low
Report
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
2/27
09:16 am
tgtx
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:37 pm
tgtx
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/26
02:17 pm
tgtx
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
2/26
12:37 pm
tgtx
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
Neutral
Report
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]